Vaxcyte, Inc. — Director's Dealing 2022

Aug 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-08-25

Reporting Person: GUGGENHIME ANDREW (President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-25	Common Stock	M	17052	$5.35	Acquired	59239	Direct
2022-08-25	Common Stock	S	17052	$28.00	Disposed	42187	Direct
2022-08-26	Common Stock	M	1295	$5.35	Acquired	43482	Direct
2022-08-26	Common Stock	S	1295	$28.00	Disposed	42187	Direct
2022-08-29	Common Stock	M	17653	$5.35	Acquired	59840	Direct
2022-08-29	Common Stock	S	17653	$28.00	Disposed	42187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-25	Stock Option (right to buy)	$5.35	M	17052	Disposed	2030-05-11	Common Stock (17052)	Direct
2022-08-26	Stock Option (right to buy)	$5.35	M	1295	Disposed	2030-05-11	Common Stock (1295)	Direct
2022-08-29	Stock Option (right to buy)	$5.35	M	17653	Disposed	2030-05-11	Common Stock (17653)	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.